BioCryst Pharmaceuticals
BCRX
98 hedge funds and large institutions have $588M invested in BioCryst Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 14 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
39% more call options, than puts
Call options by funds: $3.96M | Put options by funds: $2.85M
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
8% more funds holding
Funds holding: 91 → 98 (+7)
20% less capital invested
Capital invested by funds: $739M → $588M (-$151M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$24.2M |
| 2 |
Jennison Associates
New York
|
+$10.1M |
| 3 |
Goldman Sachs
New York
|
+$8.01M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.82M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.22M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$2.84M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2.56M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$2.44M |
BCRX Hedge Fund Activity: Q1 2015 in Review
98 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2015, worth a combined $588M — down 20% from $739M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new BCRX positions and 14 closed out — a net gain of 7 holders — while 35 added to existing stakes and 26 trimmed.
The largest buyer was Millennium Management, adding an estimated $24.2M. The largest seller was Wellington Management Group, cutting an estimated $3.82M.
- 98 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2015, up from 91 in Q4 2014.
- Funds reported $588M of BioCryst Pharmaceuticals stock for Q1 2015, down 20% quarter-over-quarter.
- 21 funds opened new BioCryst Pharmaceuticals positions in Q1 2015 and 14 closed out, a net change of +7 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2015 was Millennium Management, an estimated $24.2M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2015 was Wellington Management Group, an estimated $3.82M sold.
Based on aggregated 13F filings for Q1 2015.